{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:16:42Z","timestamp":1792801002750,"version":"4.5.0"},"reference-count":311,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5494"],"award-info":[{"award-number":["2024JJ5494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Natural Science Foundation of Changsha City","award":["Kq2403094"],"award-info":[{"award-number":["Kq2403094"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Innovative Province Construction Special Project","award":["2021ZK4025"],"award-info":[{"award-number":["2021ZK4025"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Development and Reform Commission of Innovative Research Program","award":["2021-212-23"],"award-info":[{"award-number":["2021-212-23"]}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunan Provincial Department of Finance Gra","award":["2024-31, 45, 2022-151, 2021-139 and 2020-83"],"award-info":[{"award-number":["2024-31, 45, 2022-151, 2021-139 and 2020-83"]}],"id":[{"id":"https:\/\/ror.org\/01p6gx185","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02476-7","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:29:48Z","timestamp":1762252188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives"],"prefix":"10.1186","volume":"24","author":[{"given":"Dong","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaokai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhuo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"3","key":"2476_CR1","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","volume":"21","author":"AK Singh","year":"2020","unstructured":"Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21(3):e168\u201378.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2476_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/INMD.20230047","volume":"2","author":"K Qian","year":"2024","unstructured":"Qian K, et al. CAR-T-cell products in solid tumors: progress, challenges, and strategies. Interdiscip Med. 2024;2(2):e20230047.","journal-title":"Interdiscip Med"},{"issue":"7","key":"2476_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","volume":"22","author":"GI Ellis","year":"2021","unstructured":"Ellis GI, Sheppard NC, Riley JL. Genetic engineering of T cells for immunotherapy. Nat Rev Genet. 2021;22(7):427\u201347.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"2476_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2476_CR5","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452\u201365.","journal-title":"Mol Ther"},{"issue":"2","key":"2476_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/sj.cdd.4402244","volume":"15","author":"SP Cullen","year":"2008","unstructured":"Cullen SP, Martin SJ. Mechanisms of granule-dependent killing. Cell Death Differ. 2008;15(2):251\u201362.","journal-title":"Cell Death Differ"},{"key":"2476_CR7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36688","author":"MA Morrissey","year":"2018","unstructured":"Morrissey MA, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018. https:\/\/doi.org\/10.7554\/eLife.36688.","journal-title":"Elife"},{"key":"2476_CR8","doi-asserted-by":"publisher","first-page":"1041073","DOI":"10.3389\/fphar.2022.1041073","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Activation of cancer immunotherapy by nanomedicine. Front Pharmacol. 2022;13:1041073.","journal-title":"Front Pharmacol"},{"key":"2476_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax7969","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/sciimmunol.aax7969.","journal-title":"Sci Immunol"},{"issue":"7575","key":"2476_CR10","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi J, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660\u20135.","journal-title":"Nature"},{"issue":"2","key":"2476_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong T, et al. Damp-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20(2):95\u2013112.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2476_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1158\/2326-6066.CIR-20-0525","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhang Y, Lieberman J. Lighting a fire: can we harness pyroptosis to ignite antitumor immunity?? Cancer Immunol Res. 2021;9(1):2\u20137.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2476_CR13","first-page":"100","volume":"2","author":"VG Kravets","year":"2017","unstructured":"Kravets VG, Zhang Y, Sun H. Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy. J Immunol Res Ther. 2017;2(1):100\u201313.","journal-title":"J Immunol Res Ther"},{"issue":"5","key":"2476_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove R, et al. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049.","journal-title":"Clin Transl Immunol"},{"key":"2476_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells11233839","author":"DC Harrer","year":"2022","unstructured":"Harrer DC, et al. CAR triggered release of type-1 interferon limits CAR T-cell activities by an artificial negative autocrine loop. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11233839.","journal-title":"Cells"},{"key":"2476_CR16","doi-asserted-by":"publisher","first-page":"1335424","DOI":"10.3389\/fimmu.2024.1335424","volume":"15","author":"S Smirnov","year":"2024","unstructured":"Smirnov S, et al. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol. 2024;15:1335424.","journal-title":"Front Immunol"},{"key":"2476_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071493","author":"C Moreno","year":"2022","unstructured":"Moreno C, et al. Alternative CAR therapies: recent approaches in engineering chimeric antigen receptor immune cells to combat cancer. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10071493.","journal-title":"Biomedicines"},{"issue":"6","key":"2476_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2114254","volume":"18","author":"T Asmamaw Dejenie","year":"2022","unstructured":"Asmamaw Dejenie T, et al. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccin Immunother. 2022;18(6):2114254.","journal-title":"Hum Vaccin Immunother"},{"key":"2476_CR19","first-page":"377","volume":"33","author":"C Zhu","year":"2024","unstructured":"Zhu C, et al. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment. Bioact Mater. 2024;33:377\u201395.","journal-title":"Bioact Mater"},{"key":"2476_CR20","doi-asserted-by":"crossref","unstructured":"Lee A. Obecabtagene autoleucel: first approval. Mol Diagn Ther. 2025;29(3): 419\u201323.","DOI":"10.1007\/s40291-025-00771-z"},{"issue":"6576","key":"2476_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136.","journal-title":"Science"},{"issue":"10","key":"2476_CR22","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, et al. Anti-CD19 CAR t cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"issue":"1","key":"2476_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin H, et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 2025;18(1):62.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2476_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.hlife.2024.05.005","volume":"2","author":"W Zhang","year":"2024","unstructured":"Zhang W, et al. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife. 2024;2(8):434\u20138.","journal-title":"hLife"},{"issue":"12","key":"2476_CR25","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","volume":"41","author":"M Elsallab","year":"2023","unstructured":"Elsallab M, Maus MV. Expanding access to CAR t cell therapies through local manufacturing. Nat Biotechnol. 2023;41(12):1698\u2013708.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2476_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","volume":"11","author":"H Dana","year":"2021","unstructured":"Dana H, et al. CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021;11(5):1129\u201347.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"2476_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.","journal-title":"J Exp Clin Cancer Res"},{"issue":"14","key":"2476_CR28","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273\u201390.","journal-title":"Theranostics"},{"issue":"26","key":"2476_CR29","doi-asserted-by":"publisher","first-page":"7981","DOI":"10.7150\/thno.37568","volume":"9","author":"M Saeed","year":"2019","unstructured":"Saeed M, et al. Engineering nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy. Theranostics. 2019;9(26):7981\u20138000.","journal-title":"Theranostics"},{"issue":"10","key":"2476_CR30","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2910349","volume":"29","author":"N Dhas","year":"2024","unstructured":"Dhas N, et al. Nanoengineered platform-based microenvironment-triggered immunotherapy in cancer treatment. Front Biosci (Landmark Ed). 2024;29(10):349.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"2476_CR31","doi-asserted-by":"publisher","first-page":"27934","DOI":"10.31083\/FBL27934","volume":"30","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Cui Y, Sun Y. Brain-targeting nanoparticle drug delivery systems for brain tumors. Front Biosci (Landmark Ed). 2025;30(1):27934.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2476_CR32","doi-asserted-by":"crossref","unstructured":"Kalayil N, Budar AA, Dave RK. Nanofibers for drug delivery: design and fabrication strategies. BIOI' 2024;5(1):1\u201318.","DOI":"10.15212\/bioi-2024-0023"},{"issue":"3","key":"2476_CR33","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM, et al. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 2020;20(3):1578\u201389.","journal-title":"Nano Lett"},{"issue":"13","key":"2476_CR34","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/smll.201402369","volume":"11","author":"RA Meyer","year":"2015","unstructured":"Meyer RA, et al. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small. 2015;11(13):1519\u201325.","journal-title":"Small"},{"key":"2476_CR35","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","volume":"353","author":"IS Pinto","year":"2023","unstructured":"Pinto IS, Cordeiro RA, Faneca H. Polymer- and lipid-based gene delivery technology for CAR T cell therapy. J Control Release. 2023;353:196\u2013215.","journal-title":"J Control Release"},{"issue":"7","key":"2476_CR36","first-page":"1973","volume":"6","author":"M Yang","year":"2021","unstructured":"Yang M, et al. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2021;6(7):1973\u201387.","journal-title":"Bioact Mater"},{"issue":"4","key":"2476_CR37","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1021\/nn500962q","volume":"8","author":"LK Bogart","year":"2014","unstructured":"Bogart LK, et al. Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano. 2014;8(4):3107\u201322.","journal-title":"ACS Nano"},{"issue":"1","key":"2476_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","volume":"16","author":"N Gong","year":"2021","unstructured":"Gong N, et al. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16(1):25\u201336.","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"2476_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"2476_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217083","volume":"597","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, et al. The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: mystery of the sphinx? Cancer Lett. 2024;597:217083.","journal-title":"Cancer Lett"},{"issue":"9","key":"2476_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.31083\/j.fbl2809206","volume":"28","author":"S Zhou","year":"2023","unstructured":"Zhou S, et al. Present status and advances in chimeric antigen receptor T cell therapy for glioblastoma. Front Biosci (Landmark Ed). 2023;28(9):206.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2476_CR42","doi-asserted-by":"publisher","DOI":"10.34133\/bmr.0045","volume":"28","author":"G Yu","year":"2024","unstructured":"Yu G, et al. Recent advancements in biomaterials for chimeric antigen receptor T cell immunotherapy. Biomater Res. 2024;28:0045.","journal-title":"Biomater Res"},{"issue":"8","key":"2476_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.hlife.2024.06.002","volume":"2","author":"L Yan","year":"2024","unstructured":"Yan L, et al. Boosting CAR-T cell therapy with CRISPR technology. hLife. 2024;2(8):380\u201396.","journal-title":"hLife"},{"key":"2476_CR44","doi-asserted-by":"publisher","first-page":"886546","DOI":"10.3389\/fimmu.2022.886546","volume":"13","author":"AN Khan","year":"2022","unstructured":"Khan AN, et al. Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation. Front Immunol. 2022;13:886546.","journal-title":"Front Immunol"},{"issue":"7926","key":"2476_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609(7926):369\u201374.","journal-title":"Nature"},{"key":"2476_CR46","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.2147\/IJN.S424723","volume":"18","author":"P Prazeres","year":"2023","unstructured":"Prazeres P, et al. Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells. Int J Nanomed. 2023;18:5891\u2013904.","journal-title":"Int J Nanomed"},{"issue":"8","key":"2476_CR47","doi-asserted-by":"publisher","first-page":"e2301300","DOI":"10.1002\/smtd.202301300","volume":"8","author":"T Hu","year":"2024","unstructured":"Hu T, et al. Automating CAR-T transfection with micro and Nano-Technologies. Small Methods. 2024;8(8):e2301300.","journal-title":"Small Methods"},{"issue":"4","key":"2476_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13791","volume":"58","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, et al. Revolutionising cancer immunotherapy: advancements and prospects in non-viral CAR-NK cell engineering. Cell Prolif. 2025;58(4):e13791.","journal-title":"Cell Prolif"},{"issue":"1","key":"2476_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3066","volume":"37","author":"E Harris","year":"2021","unstructured":"Harris E, Elmer JJ. Optimization of electroporation and other non-viral gene delivery strategies for T cells. Biotechnol Prog. 2021;37(1):e3066.","journal-title":"Biotechnol Prog"},{"issue":"9","key":"2476_CR50","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jcyt.2021.03.002","volume":"23","author":"H Kavanagh","year":"2021","unstructured":"Kavanagh H, et al. A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications. Cytotherapy. 2021;23(9):852\u201360.","journal-title":"Cytotherapy"},{"issue":"6","key":"2476_CR51","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde M, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5(6):880\u201394.","journal-title":"Nat Cancer"},{"issue":"14","key":"2476_CR52","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284\u201395.","journal-title":"N Engl J Med"},{"key":"2476_CR53","doi-asserted-by":"publisher","first-page":"849759","DOI":"10.3389\/fimmu.2022.849759","volume":"13","author":"J Mi","year":"2022","unstructured":"Mi J, Ye Q, Min Y. Advances in nanotechnology development to overcome current roadblocks in CAR-T therapy for solid tumors. Front Immunol. 2022;13:849759.","journal-title":"Front Immunol"},{"key":"2476_CR54","first-page":"69","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, et al. CAR t cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther. 2022;25:69\u201377.","journal-title":"Mol Ther"},{"key":"2476_CR55","doi-asserted-by":"crossref","unstructured":"Guo Z, Saw PE, Jon S. Non-Invasive physical stimulation to modulate the tumor microenvironment: unveiling a new frontier in cancer therapy. BIOI. 2024;5(1):1\u201314.","DOI":"10.15212\/bioi-2024-0012"},{"issue":"7","key":"2476_CR56","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20(7):531\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2476_CR57","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2(9):904\u201318.","journal-title":"Nat Cancer"},{"issue":"2","key":"2476_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2476_CR59","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, et al. Car T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"2476_CR60","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, et al. Tumor inflammation-associated neurotoxicity. Nat Med. 2023;29(4):803\u201310.","journal-title":"Nat Med"},{"issue":"9","key":"2476_CR61","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41551-023-01084-4","volume":"7","author":"X Li","year":"2023","unstructured":"Li X, et al. Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. Nat Biomed Eng. 2023;7(9):1129\u201341.","journal-title":"Nat Biomed Eng"},{"key":"2476_CR62","doi-asserted-by":"crossref","unstructured":"Sakemura RL, Manriquez Roman C, Horvei P et al. ,. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood. 2024;143(3):258\u2013271. Blood, 2024. 144(14): p. 1544.","DOI":"10.1182\/blood.2024026723"},{"issue":"1","key":"2476_CR63","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, et al. Single-Cell analyses identify brain mural cells expressing CD19 as potential Off-Tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126\u2013e14217.","journal-title":"Cell"},{"key":"2476_CR64","doi-asserted-by":"crossref","unstructured":"Jess J, et al. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. J Immunother Cancer. 2023;11(6):e005898.","DOI":"10.1136\/jitc-2022-005898"},{"key":"2476_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634445","volume":"11","author":"BD Brown","year":"2021","unstructured":"Brown BD, et al. Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis?? Front Oncol. 2021;11:634445.","journal-title":"Front Oncol"},{"issue":"17","key":"2476_CR66","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","volume":"28","author":"C Diorio","year":"2022","unstructured":"Diorio C, et al. Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-cell ALL receiving CAR T19. Clin Cancer Res. 2022;28(17):3804\u201313.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2476_CR67","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41563-023-01646-6","volume":"22","author":"N Gong","year":"2023","unstructured":"Gong N, et al. In situ pegylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity. Nat Mater. 2023;22(12):1571\u201380.","journal-title":"Nat Mater"},{"issue":"7","key":"2476_CR68","first-page":"e4381","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, et al. Immune effector Cell-Associated hemophagocytic Lymphohistiocytosis-Like syndrome. Transpl Cell Ther. 2023;29(7):e4381\u201343816.","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2476_CR69","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","volume":"10","author":"Jr. AD Posey","year":"2024","unstructured":"Posey AD Jr., Young RM, June CH. Future perspectives on engineered T cells for cancer. Trends Cancer. 2024;10(8):687\u201395.","journal-title":"Trends Cancer"},{"key":"2476_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076300","author":"RC De Marco","year":"2023","unstructured":"De Marco RC, Monzo HJ, Ojala PM. CAR T cell therapy: a versatile living drug. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076300.","journal-title":"Int J Mol Sci"},{"key":"2476_CR71","doi-asserted-by":"publisher","first-page":"867013","DOI":"10.3389\/fimmu.2022.867013","volume":"13","author":"A Moretti","year":"2022","unstructured":"Moretti A, et al. The past, present, and future of non-viral CAR T cells. Front Immunol. 2022;13:867013.","journal-title":"Front Immunol"},{"key":"2476_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf1333","author":"M Bozza","year":"2021","unstructured":"Bozza M, et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abf1333.","journal-title":"Sci Adv"},{"issue":"4","key":"2476_CR73","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ymthe.2019.01.018","volume":"27","author":"JB Foster","year":"2019","unstructured":"Foster JB, Barrett DM, Karik\u00f3 K. The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy. Mol Ther. 2019;27(4):747\u201356.","journal-title":"Mol Ther"},{"issue":"20","key":"2476_CR74","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1002\/smll.201502930","volume":"12","author":"Y Cheng","year":"2016","unstructured":"Cheng Y, et al. Nano-Sized sunflower polycations as effective gene transfer vehicles. Small. 2016;12(20):2750\u20138.","journal-title":"Small"},{"key":"2476_CR75","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jconrel.2018.02.043","volume":"282","author":"BR Olden","year":"2018","unstructured":"Olden BR, et al. Cationic polymers for non-viral gene delivery to human T cells. J Control Release. 2018;282:140\u20137.","journal-title":"J Control Release"},{"issue":"1","key":"2476_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s40820-020-00523-0","volume":"12","author":"L Raes","year":"2020","unstructured":"Raes L, et al. Intracellular delivery of mRNA in adherent and suspension cells by vapor nanobubble photoporation. Nano-Micro Lett. 2020;12(1):185.","journal-title":"Nano-Micro Lett"},{"issue":"2","key":"2476_CR77","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.19988","volume":"206","author":"Z Chen","year":"2025","unstructured":"Chen Z, et al. mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells. Br J Haematol. 2025;206(2):628\u201343.","journal-title":"Br J Haematol"},{"issue":"1","key":"2476_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/INMD.20230036","volume":"2","author":"K Xiao","year":"2024","unstructured":"Xiao K, et al. mRNA-based chimeric antigen receptor T cell therapy: basic principles, recent advances and future directions. Interdiscip Med. 2024;2(1):e20230036.","journal-title":"Interdiscip Med"},{"issue":"1","key":"2476_CR79","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","volume":"22","author":"MM Billingsley","year":"2022","unstructured":"Billingsley MM, et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 2022;22(1):533\u201342.","journal-title":"Nano Lett"},{"issue":"2","key":"2476_CR80","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","volume":"8","author":"Z Ye","year":"2022","unstructured":"Ye Z, et al. Vitro engineering chimeric antigen receptor macrophages and T cells by lipid Nanoparticle-Mediated mRNA delivery. ACS Biomater Sci Eng. 2022;8(2):722\u201333.","journal-title":"ACS Biomater Sci Eng"},{"issue":"14","key":"2476_CR81","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.7150\/thno.19017","volume":"7","author":"C Wang","year":"2017","unstructured":"Wang C, et al. Bioengineering of artificial antigen presenting cells and lymphoid organs. Theranostics. 2017;7(14):3504\u201316.","journal-title":"Theranostics"},{"issue":"12","key":"2476_CR82","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.1021\/acsnano.3c10180","volume":"18","author":"F Hou","year":"2024","unstructured":"Hou F, et al. Particle-based artificial antigen-presenting cell systems for T cell activation in adoptive T cell therapy. ACS Nano. 2024;18(12):8571\u201399.","journal-title":"ACS Nano"},{"issue":"8","key":"2476_CR83","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nnano.2014.154","volume":"9","author":"TR Fadel","year":"2014","unstructured":"Fadel TR, et al. A carbon nanotube-polymer composite for T-cell therapy. Nat Nanotechnol. 2014;9(8):639\u201347.","journal-title":"Nat Nanotechnol"},{"key":"2476_CR84","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1479-5876-8-104","volume":"8","author":"Y Li","year":"2010","unstructured":"Li Y, Kurlander RJ. Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med. 2010;8:104.","journal-title":"J Transl Med"},{"issue":"26","key":"2476_CR85","doi-asserted-by":"publisher","first-page":"e2313226","DOI":"10.1002\/adma.202313226","volume":"36","author":"AE Metzloff","year":"2024","unstructured":"Metzloff AE, et al. Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy. Adv Mater. 2024;36(26):e2313226.","journal-title":"Adv Mater"},{"key":"2476_CR86","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijbiomac.2021.09.129","volume":"192","author":"N Moradi","year":"2021","unstructured":"Moradi N, et al. Bio-conjugation of anti-human CD3 monoclonal antibodies to magnetic nanoparticles by using cyanogen bromide: a potential for cell sorting and noninvasive diagnosis. Int J Biol Macromol. 2021;192:72\u201381.","journal-title":"Int J Biol Macromol"},{"issue":"12","key":"2476_CR87","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1021\/acs.nanolett.2c01018","volume":"22","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Nanoparticle amplification labeling for high-performance magnetic cell sorting. Nano Lett. 2022;22(12):4774\u201383.","journal-title":"Nano Lett"},{"key":"2476_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115448","volume":"214","author":"E Garbayo","year":"2024","unstructured":"Garbayo E, et al. RNA-loaded nanoparticles for the treatment of hematological cancers. Adv Drug Deliv Rev. 2024;214:115448.","journal-title":"Adv Drug Deliv Rev"},{"key":"2476_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2017.56","author":"KA Hajj","year":"2017","unstructured":"Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017. https:\/\/doi.org\/10.1038\/natrevmats.2017.56.","journal-title":"Nat Rev Mater"},{"issue":"8","key":"2476_CR90","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813\u201320.","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"2476_CR91","doi-asserted-by":"publisher","first-page":"e2310078","DOI":"10.1002\/adma.202310078","volume":"36","author":"C Zhu","year":"2024","unstructured":"Zhu C, et al. Injectable supramolecular hydrogels for in situ programming of Car-T cells toward solid tumor immunotherapy. Adv Mater. 2024;36(5):e2310078.","journal-title":"Adv Mater"},{"key":"2476_CR92","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"JE Zhou","year":"2022","unstructured":"Zhou JE, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307.","journal-title":"J Control Release"},{"issue":"3","key":"2476_CR93","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175\u201396.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"2476_CR94","doi-asserted-by":"publisher","first-page":"e2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, et al. Vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20(11):e2304378.","journal-title":"Small"},{"issue":"4","key":"2476_CR95","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313\u201320.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"2476_CR96","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18(1):265\u201391.","journal-title":"Nat Protoc"},{"key":"2476_CR97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109256118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2109256118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"44","key":"2476_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202310395","volume":"62","author":"E \u00c1lvarez-Benedicto","year":"2023","unstructured":"\u00c1lvarez-Benedicto E, et al. Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma. Angew Chem Int Ed Engl. 2023;62(44):e202310395.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"2476_CR99","doi-asserted-by":"publisher","first-page":"6974","DOI":"10.1007\/s12274-022-5267-5","volume":"16","author":"KA Hughes","year":"2023","unstructured":"Hughes KA, et al. Use of stimulatory responsive soft nanoparticles for intracellular drug delivery. Nano Res. 2023;16(5):6974\u201390.","journal-title":"Nano Res"},{"key":"2476_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114861","volume":"197","author":"P Khare","year":"2023","unstructured":"Khare P, et al. Lipid nanoparticle-mediated drug delivery to the brain. Adv Drug Deliv Rev. 2023;197:114861.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"2476_CR101","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade1444","volume":"9","author":"JR Melamed","year":"2023","unstructured":"Melamed JR, et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 cells via macrophage-mediated gene transfer. Sci Adv. 2023;9(4):eade1444.","journal-title":"Sci Adv"},{"issue":"8","key":"2476_CR102","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1021\/jacs.2c12893","volume":"145","author":"KL Swingle","year":"2023","unstructured":"Swingle KL, et al. Ionizable lipid nanoparticles for in vivo mRNA delivery to the placenta during pregnancy. J Am Chem Soc. 2023;145(8):4691\u2013706.","journal-title":"J Am Chem Soc"},{"issue":"22","key":"2476_CR103","doi-asserted-by":"publisher","first-page":"9926","DOI":"10.1021\/jacs.2c02706","volume":"144","author":"L Xue","year":"2022","unstructured":"Xue L, et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J Am Chem Soc. 2022;144(22):9926\u201337.","journal-title":"J Am Chem Soc"},{"issue":"34","key":"2476_CR104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207841119","volume":"119","author":"J Chen","year":"2022","unstructured":"Chen J, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc Natl Acad Sci U S A. 2022;119(34):e2207841119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2476_CR105","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"G Zhao","year":"2024","unstructured":"Zhao G, et al. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci Bull. 2024;69(3):354\u201366.","journal-title":"Sci Bull"},{"issue":"3","key":"2476_CR106","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.7150\/thno.40291","volume":"10","author":"W Ma","year":"2020","unstructured":"Ma W, et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics. 2020;10(3):1281\u201395.","journal-title":"Theranostics"},{"issue":"37","key":"2476_CR107","doi-asserted-by":"publisher","first-page":"e2401299","DOI":"10.1002\/smll.202401299","volume":"20","author":"W Wu","year":"2024","unstructured":"Wu W, et al. CAR T cell membrane camouflaged nanocatalyst augments CAR T cell therapy efficacy against solid tumor. Small. 2024;20(37):e2401299.","journal-title":"Small"},{"key":"2476_CR108","first-page":"422","volume":"34","author":"S Yaman","year":"2024","unstructured":"Yaman S, et al. Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles. Bioact Mater. 2024;34:422\u201335.","journal-title":"Bioact Mater"},{"key":"2476_CR109","doi-asserted-by":"publisher","first-page":"121341","DOI":"10.1016\/j.biomaterials.2021.121341","volume":"281","author":"Y Luo","year":"2022","unstructured":"Luo Y, et al. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy. Biomaterials. 2022;281:121341.","journal-title":"Biomaterials"},{"issue":"14","key":"2476_CR110","doi-asserted-by":"publisher","first-page":"e2007494","DOI":"10.1002\/smll.202007494","volume":"17","author":"Z Chen","year":"2021","unstructured":"Chen Z, et al. Nanoengineered CAR-T biohybrids for solid tumor immunotherapy with microenvironment Photothermal-Remodeling strategy. Small. 2021;17(14):e2007494.","journal-title":"Small"},{"key":"2476_CR111","doi-asserted-by":"publisher","first-page":"100615","DOI":"10.1016\/j.mtbio.2023.100615","volume":"20","author":"Y Tang","year":"2023","unstructured":"Tang Y, et al. TGF-\u03b2 blocking combined with photothermal therapy promote tumor targeted migration and long-term antitumor activity of CAR-T cells. Mater Today Bio. 2023;20:100615.","journal-title":"Mater Today Bio"},{"issue":"2","key":"2476_CR112","doi-asserted-by":"publisher","first-page":"e2407425","DOI":"10.1002\/adma.202407425","volume":"37","author":"Q Zou","year":"2025","unstructured":"Zou Q, et al. Photo-metallo-immunotherapy: fabricating Chromium-Based nanocomposites to enhance CAR-T cell infiltration and cytotoxicity against solid tumors. Adv Mater. 2025;37(2):e2407425.","journal-title":"Adv Mater"},{"issue":"18","key":"2476_CR113","doi-asserted-by":"publisher","first-page":"e2211509","DOI":"10.1002\/adma.202211509","volume":"35","author":"X Tang","year":"2023","unstructured":"Tang X, et al. Magnetic-Acoustic sequentially actuated CAR T cell microrobots for precision navigation and in situ antitumor immunoactivation. Adv Mater. 2023;35(18):e2211509.","journal-title":"Adv Mater"},{"issue":"6","key":"2476_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303031","volume":"13","author":"Y Chen","year":"2024","unstructured":"Chen Y, et al. Intratumoral lactate depletion based on injectable nanoparticles-hydrogel composite system synergizes with immunotherapy against postablative hepatocellular carcinoma recurrence. Adv Healthc Mater. 2024;13(6):e2303031.","journal-title":"Adv Healthc Mater"},{"issue":"12","key":"2476_CR115","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41571-021-00539-4","volume":"18","author":"DC Singleton","year":"2021","unstructured":"Singleton DC, Macann A, Wilson WR. Therapeutic targeting of the hypoxic tumour microenvironment. Nat Rev Clin Oncol. 2021;18(12):751\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"2476_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100787","volume":"59","author":"J Kopecka","year":"2021","unstructured":"Kopecka J, et al. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat. 2021;59:100787.","journal-title":"Drug Resist Updat"},{"issue":"9","key":"2476_CR117","doi-asserted-by":"publisher","first-page":"e2308254","DOI":"10.1002\/adma.202308254","volume":"36","author":"Z Dong","year":"2024","unstructured":"Dong Z, et al. Tumor microenvironment modulating CaCO(3) -Based colloidosomal microreactors can generally reinforce cancer immunotherapy. Adv Mater. 2024;36(9):e2308254.","journal-title":"Adv Mater"},{"issue":"12","key":"2476_CR118","doi-asserted-by":"publisher","first-page":"11749","DOI":"10.1021\/acsnano.3c02592","volume":"17","author":"H Li","year":"2023","unstructured":"Li H, et al. A near-infrared-II fluorescent nanocatalyst for enhanced CAR T cell therapy against solid tumor by immune reprogramming. ACS Nano. 2023;17(12):11749\u201363.","journal-title":"ACS Nano"},{"key":"2476_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122750","volume":"312","author":"M Yazdimamaghani","year":"2025","unstructured":"Yazdimamaghani M, et al. Tumor microenvironment immunomodulation by nanoformulated TLR 7\/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy. Biomaterials. 2025;312:122750.","journal-title":"Biomaterials"},{"issue":"1","key":"2476_CR120","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41467-024-55751-4","volume":"16","author":"T Zhu","year":"2025","unstructured":"Zhu T, et al. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025;16(1):262.","journal-title":"Nat Commun"},{"issue":"13","key":"2476_CR121","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-18-0306","volume":"78","author":"F Zhang","year":"2018","unstructured":"Zhang F, et al. Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies. Cancer Res. 2018;78(13):3718\u201330.","journal-title":"Cancer Res"},{"issue":"3","key":"2476_CR122","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1021\/acsnano.7b00078","volume":"11","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, et al. Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or noninternalizing receptors. ACS Nano. 2017;11(3):3089\u2013100.","journal-title":"ACS Nano"},{"issue":"7","key":"2476_CR123","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","volume":"6","author":"N Siriwon","year":"2018","unstructured":"Siriwon N, et al. Car-t cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral t-cell hypofunction. Cancer Immunol Res. 2018;6(7):812\u201324.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2476_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi M, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9(1):176.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"2476_CR125","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-023-00746-x","volume":"22","author":"WJ Leonard","year":"2023","unstructured":"Leonard WJ, Lin JX. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov. 2023;22(10):827\u201354.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2476_CR126","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"2476_CR127","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6579","volume":"6","author":"CWt Shields","year":"2020","unstructured":"Shields CWt, et al. Cellular backpacks for macrophage immunotherapy. Sci Adv. 2020;6(18):eaaz6579.","journal-title":"Sci Adv"},{"issue":"8","key":"2476_CR128","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang L, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707\u201316.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2476_CR129","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213222120","volume":"120","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Cytokine conjugation to enhance T cell therapy. Proc Natl Acad Sci U S A. 2023;120(1):e2213222120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2476_CR130","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","volume":"5","author":"Q Hu","year":"2021","unstructured":"Hu Q, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5(9):1038\u201347.","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"2476_CR131","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, et al. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146\u201362.","journal-title":"Mol Ther"},{"issue":"1","key":"2476_CR132","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"key":"2476_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.139829","volume":"297","author":"H Gao","year":"2025","unstructured":"Gao H, et al. Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers. Int J Biol Macromol. 2025;297:139829.","journal-title":"Int J Biol Macromol"},{"key":"2476_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102147","volume":"51","author":"Z Wu","year":"2025","unstructured":"Wu Z, et al. Universal CAR cell therapy: challenges and expanding applications. Transl Oncol. 2025;51:102147.","journal-title":"Transl Oncol"},{"key":"2476_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107628","volume":"213","author":"B Xia","year":"2025","unstructured":"Xia B, et al. Development of chimeric nanobody-granzyme B functionalized ferritin nanoparticles for precise tumor therapy. Pharmacol Res. 2025;213:107628.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2476_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05159-x","volume":"22","author":"K Lin","year":"2024","unstructured":"Lin K, et al. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology. J Transl Med. 2024;22(1):349.","journal-title":"J Transl Med"},{"issue":"1","key":"2476_CR137","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-022-01246-y","volume":"15","author":"Z Sun","year":"2022","unstructured":"Sun Z, et al. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors. J Hematol Oncol. 2022;15(1):29.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"2476_CR138","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186(15):3148\u2013e316520.","journal-title":"Cell"},{"issue":"15","key":"2476_CR139","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell. 2022;185(15):2770\u201388.","journal-title":"Cell"},{"issue":"11","key":"2476_CR140","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","volume":"32","author":"Z Chen","year":"2024","unstructured":"Chen Z, et al. Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy. Mol Ther. 2024;32(11):3772\u201392.","journal-title":"Mol Ther"},{"key":"2476_CR141","doi-asserted-by":"publisher","first-page":"120584","DOI":"10.1016\/j.biomaterials.2020.120584","volume":"268","author":"A Isser","year":"2021","unstructured":"Isser A, Livingston NK, Schneck JP. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomaterials. 2021;268:120584.","journal-title":"Biomaterials"},{"issue":"1","key":"2476_CR142","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12951-023-01900-8","volume":"21","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach. J Nanobiotechnol. 2023;21(1):159.","journal-title":"J Nanobiotechnol"},{"issue":"11","key":"2476_CR143","doi-asserted-by":"publisher","first-page":"18408","DOI":"10.1021\/acsnano.2c06516","volume":"16","author":"H Zang","year":"2022","unstructured":"Zang H, et al. Ganglioside-functionalized nanoparticles for chimeric antigen receptor T-cell activation at the immunological synapse. ACS Nano. 2022;16(11):18408\u201320.","journal-title":"ACS Nano"},{"issue":"65","key":"2476_CR144","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf4034","volume":"6","author":"JR Kuchroo","year":"2021","unstructured":"Kuchroo JR, et al. The double-edged sword: harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol. 2021;6(65):eabf4034.","journal-title":"Sci Immunol"},{"issue":"1","key":"2476_CR145","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","volume":"12","author":"H Wang","year":"2019","unstructured":"Wang H, et al. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12(1):59.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2476_CR146","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","volume":"30","author":"YH Lee","year":"2022","unstructured":"Lee YH, et al. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther. 2022;30(2):579\u201392.","journal-title":"Mol Ther"},{"issue":"722","key":"2476_CR147","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg6752","volume":"15","author":"S Ma","year":"2023","unstructured":"Ma S, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023;15(722):eadg6752.","journal-title":"Sci Transl Med"},{"issue":"30","key":"2476_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301515","volume":"12","author":"AG Hamilton","year":"2023","unstructured":"Hamilton AG, et al. Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering. Adv Healthc Mater. 2023;12(30):e2301515.","journal-title":"Adv Healthc Mater"},{"key":"2476_CR149","doi-asserted-by":"publisher","first-page":"102591","DOI":"10.1016\/j.nano.2022.102591","volume":"45","author":"X Chen","year":"2022","unstructured":"Chen X, et al. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. Nanomedicine. 2022;45:102591.","journal-title":"Nanomedicine"},{"key":"2476_CR150","doi-asserted-by":"crossref","unstructured":"Hao M, et al. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci Transl Med. 2020;12(571):eaaz6667.","DOI":"10.1126\/scitranslmed.aaz6667"},{"issue":"8","key":"2476_CR151","doi-asserted-by":"publisher","first-page":"12695","DOI":"10.1021\/acsnano.2c04420","volume":"16","author":"ZY Al Subeh","year":"2022","unstructured":"Al Subeh ZY, et al. Lipid nanoparticle delivery of Fas plasmid restores Fas expression to suppress melanoma growth in vivo. ACS Nano. 2022;16(8):12695\u2013710.","journal-title":"ACS Nano"},{"issue":"9","key":"2476_CR152","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","volume":"33","author":"MR Collinson-Pautz","year":"2019","unstructured":"Collinson-Pautz MR, et al. Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia. 2019;33(9):2195\u2013207.","journal-title":"Leukemia"},{"issue":"3","key":"2476_CR153","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/leu.2017.249","volume":"32","author":"Y Lai","year":"2018","unstructured":"Lai Y, et al. Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T cells. Leukemia. 2018;32(3):801\u20138.","journal-title":"Leukemia"},{"issue":"11","key":"2476_CR154","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","volume":"7","author":"M Mata","year":"2017","unstructured":"Mata M, et al. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. 2017;7(11):1306\u201319.","journal-title":"Cancer Discov"},{"issue":"2","key":"2476_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200815","volume":"32","author":"V Mikoli\u010d","year":"2024","unstructured":"Mikoli\u010d V, et al. Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors. Mol Ther Oncol. 2024;32(2):200815.","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"2476_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0642-9","volume":"7","author":"D Yang","year":"2019","unstructured":"Yang D, et al. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer. 2019;7(1):171.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2476_CR157","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1073\/pnas.0400171101","volume":"101","author":"M Komai-Koma","year":"2004","unstructured":"Komai-Koma M, et al. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A. 2004;101(9):3029\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2476_CR158","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-019-0816-4","volume":"12","author":"J Weng","year":"2019","unstructured":"Weng J, et al. A novel generation 1928zt2 car t cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 2019;12(1):117.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2476_CR159","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.ymthe.2017.06.014","volume":"25","author":"AE Foster","year":"2017","unstructured":"Foster AE, et al. Regulated expansion and survival of chimeric antigen Receptor-Modified T cells using small molecule-dependent inducible MyD88\/CD40. Mol Ther. 2017;25(9):2176\u201388.","journal-title":"Mol Ther"},{"key":"2476_CR160","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136093","author":"B Prinzing","year":"2020","unstructured":"Prinzing B, et al. MyD88\/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.136093.","journal-title":"JCI Insight"},{"key":"2476_CR161","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fimmu.2018.00441","volume":"9","author":"FM Wensveen","year":"2018","unstructured":"Wensveen FM, Jelen\u010di\u0107 V, Poli\u0107 B. NKG2D: a master regulator of immune cell responsiveness. Front Immunol. 2018;9:441.","journal-title":"Front Immunol"},{"issue":"1","key":"2476_CR162","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","volume":"29","author":"YY Ng","year":"2021","unstructured":"Ng YY, et al. Cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication. Mol Ther. 2021;29(1):75\u201385.","journal-title":"Mol Ther"},{"issue":"3","key":"2476_CR163","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10(3):e191\u2013202.","journal-title":"Lancet Haematol"},{"key":"2476_CR164","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.02.034","volume":"164","author":"H Kim","year":"2018","unstructured":"Kim H, et al. Polymeric nanoparticles encapsulating novel TLR7\/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 2018;164:38\u201353.","journal-title":"Biomaterials"},{"key":"2476_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115135","volume":"203","author":"L Liu","year":"2023","unstructured":"Liu L, et al. Cellular and molecular imaging of CAR-T cell-based immunotherapy. Adv Drug Deliv Rev. 2023;203:115135.","journal-title":"Adv Drug Deliv Rev"},{"key":"2476_CR166","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102363119","author":"L Kiru","year":"2022","unstructured":"Kiru L, et al. In vivo imaging of nanoparticle-labeled CAR T cells. Proc Natl Acad Sci U S A. 2022. https:\/\/doi.org\/10.1073\/pnas.2102363119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2476_CR167","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.7150\/thno.87248","volume":"13","author":"J Hunger","year":"2023","unstructured":"Hunger J, et al. In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma. Theranostics. 2023;13(15):5170\u201382.","journal-title":"Theranostics"},{"issue":"5","key":"2476_CR168","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ajh.21656","volume":"85","author":"M Lu","year":"2010","unstructured":"Lu M, et al. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85(5):315\u20139.","journal-title":"Am J Hematol"},{"issue":"6","key":"2476_CR169","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/RLI.0000000000000946","volume":"58","author":"WE Wu","year":"2023","unstructured":"Wu WE, et al. Multimodal in vivo tracking of chimeric antigen receptor T cells in preclinical glioblastoma models. Invest Radiol. 2023;58(6):388\u201395.","journal-title":"Invest Radiol"},{"key":"2476_CR170","doi-asserted-by":"publisher","first-page":"120630","DOI":"10.1016\/j.biomaterials.2020.120630","volume":"269","author":"S Harmsen","year":"2021","unstructured":"Harmsen S, et al. A dual-modal pet\/near infrared fluorescent nanotag for long-term immune cell tracking. Biomaterials. 2021;269:120630.","journal-title":"Biomaterials"},{"issue":"12","key":"2476_CR171","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202205044","volume":"10","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Nanomodified switch induced precise and moderate activation of CAR-T cells for solid tumors. Adv Sci. 2023;10(12):e2205044.","journal-title":"Adv Sci"},{"issue":"12","key":"2476_CR172","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","volume":"16","author":"NT Nguyen","year":"2021","unstructured":"Nguyen NT, et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021;16(12):1424\u201334.","journal-title":"Nat Nanotechnol"},{"key":"2476_CR173","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-1-0716-3593-3_17","volume":"2748","author":"NT Nguyen","year":"2024","unstructured":"Nguyen NT, et al. Nano-optogenetic CAR-T cell immunotherapy. Methods Mol Biol. 2024;2748:267\u201378.","journal-title":"Methods Mol Biol"},{"issue":"11","key":"2476_CR174","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","volume":"5","author":"IC Miller","year":"2021","unstructured":"Miller IC, et al. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nat Biomed Eng. 2021;5(11):1348\u201359.","journal-title":"Nat Biomed Eng"},{"key":"2476_CR175","doi-asserted-by":"crossref","unstructured":"Pfister F et al. Loading of CAR-T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism. MedComm (2020), 2025. 6(1): p. e70039.","DOI":"10.1002\/mco2.70039"},{"key":"2476_CR176","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2147\/IJN.S402320","volume":"18","author":"H Unterweger","year":"2023","unstructured":"Unterweger H, et al. Comparative in vitro and in vivo evaluation of different iron Oxide-Based contrast agents to promote clinical translation in compliance with patient safety. Int J Nanomed. 2023;18:2071\u201386.","journal-title":"Int J Nanomed"},{"issue":"4","key":"2476_CR177","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","volume":"23","author":"EI Buzas","year":"2023","unstructured":"Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23(4):236\u201350.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2476_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12321-3","volume":"10","author":"W Fu","year":"2019","unstructured":"Fu W, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10(1):4355.","journal-title":"Nat Commun"},{"key":"2476_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061401","author":"S Haque","year":"2021","unstructured":"Haque S, Vaiselbuh SR. CD19 chimeric antigen receptor-exosome targets CD19 positive B-lineage acute lymphocytic leukemia and induces cytotoxicity. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13061401.","journal-title":"Cancers (Basel)"},{"key":"2476_CR180","doi-asserted-by":"crossref","unstructured":"Storci G, et al. CAR\u2009+\u2009extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells. J Clin Invest. 2024;134(14):e173096.","DOI":"10.1172\/JCI173096"},{"issue":"1","key":"2476_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, et al. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8(1):293.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2476_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01460-2","volume":"16","author":"J Li","year":"2023","unstructured":"Li J, et al. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies. J Hematol Oncol. 2023;16(1):65.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2476_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010106","volume":"14","author":"AA Halwani","year":"2022","unstructured":"Halwani AA. Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics. 2022;14(1):106.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2476_CR184","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/smll.200901006","volume":"6","author":"A Fran\u00e7a","year":"2010","unstructured":"Fran\u00e7a A, et al. Sterilization matters: consequences of different sterilization techniques on gold nanoparticles. Small. 2010;6(1):89\u201395.","journal-title":"Small"},{"issue":"4","key":"2476_CR185","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0142-9612(96)00144-5","volume":"18","author":"V Masson","year":"1997","unstructured":"Masson V, et al. Influence of sterilization processes on poly(epsilon-caprolactone) nanospheres. Biomaterials. 1997;18(4):327\u201335.","journal-title":"Biomaterials"},{"key":"2476_CR186","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejpb.2018.05.016","volume":"129","author":"KJ Geh","year":"2018","unstructured":"Geh KJ, Hubert M, Winter G. Progress in formulation development and sterilisation of freeze-dried oligodeoxynucleotide-loaded gelatine nanoparticles. Eur J Pharm Biopharm. 2018;129:10\u201320.","journal-title":"Eur J Pharm Biopharm"},{"key":"2476_CR187","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26072068","author":"SA Bernal-Ch\u00e1vez","year":"2021","unstructured":"Bernal-Ch\u00e1vez SA, et al. Insights into terminal sterilization processes of nanoparticles for biomedical applications. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26072068.","journal-title":"Molecules"},{"key":"2476_CR188","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jconrel.2023.06.038","volume":"360","author":"SF Tehrani","year":"2023","unstructured":"Tehrani SF, et al. Purification processes of polymeric nanoparticles: how to improve their clinical translation? J Control Release. 2023;360:591\u2013612.","journal-title":"J Control Release"},{"issue":"12","key":"2476_CR189","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1039\/D3MH00717K","volume":"10","author":"SK Filippov","year":"2023","unstructured":"Filippov SK, et al. Dynamic light scattering and transmission electron microscopy in drug delivery: a roadmap for correct characterization of nanoparticles and interpretation of results. Mater Horiz. 2023;10(12):5354\u201370.","journal-title":"Mater Horiz"},{"issue":"5","key":"2476_CR190","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.dental.2021.02.007","volume":"37","author":"NK Carvalho","year":"2021","unstructured":"Carvalho NK, et al. Antibacterial, biological, and physicochemical properties of root canal sealers containing chlorhexidine-hexametaphosphate nanoparticles. Dent Mater. 2021;37(5):863\u201374.","journal-title":"Dent Mater"},{"issue":"5","key":"2476_CR191","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1021\/acsnano.2c02347","volume":"16","author":"Y Xu","year":"2022","unstructured":"Xu Y, et al. Surface modification of lipid-based nanoparticles. ACS Nano. 2022;16(5):7168\u201396.","journal-title":"ACS Nano"},{"key":"2476_CR192","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99Pt A","author":"JS Suk","year":"2016","unstructured":"Suk JS, et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99Pt A:28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2476_CR193","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","volume":"29","author":"R Bajracharya","year":"2022","unstructured":"Bajracharya R, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv. 2022;29(1):1959\u201370.","journal-title":"Drug Deliv"},{"issue":"8","key":"2476_CR194","doi-asserted-by":"publisher","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","volume":"13","author":"GT Kozma","year":"2019","unstructured":"Kozma GT, et al. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions. ACS Nano. 2019;13(8):9315\u201324.","journal-title":"ACS Nano"},{"issue":"9","key":"2476_CR195","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"BM Chen","year":"2021","unstructured":"Chen BM, Cheng TL, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-Polyethylene glycol antibodies. ACS Nano. 2021;15(9):14022\u201348.","journal-title":"ACS Nano"},{"issue":"1","key":"2476_CR196","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","volume":"307","author":"DE Owens","year":"2006","unstructured":"Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93\u2013102.","journal-title":"Int J Pharm"},{"issue":"1","key":"2476_CR197","doi-asserted-by":"publisher","first-page":"10542","DOI":"10.1038\/s41598-017-10836-7","volume":"7","author":"A Almalik","year":"2017","unstructured":"Almalik A, et al. Hyaluronic acid coated chitosan nanoparticles reduced the immunogenicity of the formed protein corona. Sci Rep. 2017;7(1):10542.","journal-title":"Sci Rep"},{"key":"2476_CR198","doi-asserted-by":"publisher","first-page":"121676","DOI":"10.1016\/j.biomaterials.2022.121676","volume":"287","author":"K Shin","year":"2022","unstructured":"Shin K, et al. Polyglycerol and Poly(ethylene glycol) exhibit different effects on pharmacokinetics and antibody generation when grafted to nanoparticle surfaces. Biomaterials. 2022;287:121676.","journal-title":"Biomaterials"},{"key":"2476_CR199","doi-asserted-by":"publisher","first-page":"121086","DOI":"10.1016\/j.biomaterials.2021.121086","volume":"277","author":"A Joseph","year":"2021","unstructured":"Joseph A, et al. Surfactants influence polymer nanoparticle fate within the brain. Biomaterials. 2021;277:121086.","journal-title":"Biomaterials"},{"key":"2476_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236056","author":"JW Shreffler","year":"2019","unstructured":"Shreffler JW, et al. Overcoming hurdles in nanoparticle clinical translation: the influence of experimental design and surface modification. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20236056.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2476_CR201","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/17425247.2016.1244187","volume":"14","author":"H Ragelle","year":"2017","unstructured":"Ragelle H, et al. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv. 2017;14(7):851\u201364.","journal-title":"Expert Opin Drug Deliv"},{"issue":"5761","key":"2476_CR202","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.1114397","volume":"311","author":"A Nel","year":"2006","unstructured":"Nel A, et al. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622\u20137.","journal-title":"Science"},{"issue":"3","key":"2476_CR203","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1183\/09031936.00178308","volume":"34","author":"Y Song","year":"2009","unstructured":"Song Y, Li X, Du X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J. 2009;34(3):559\u201367.","journal-title":"Eur Respir J"},{"issue":"11","key":"2476_CR204","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","volume":"19","author":"P Joyce","year":"2024","unstructured":"Joyce P, et al. A translational framework to DELIVER nanomedicines to the clinic. Nat Nanotechnol. 2024;19(11):1597\u2013611.","journal-title":"Nat Nanotechnol"},{"issue":"12","key":"2476_CR205","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394.","journal-title":"Nat Rev Mater"},{"issue":"3","key":"2476_CR206","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","volume":"159","author":"DM Chopyk","year":"2020","unstructured":"Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology. 2020;159(3):849\u201363.","journal-title":"Gastroenterology"},{"issue":"4","key":"2476_CR207","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","volume":"10","author":"HH Gustafson","year":"2015","unstructured":"Gustafson HH, et al. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015;10(4):487\u2013510.","journal-title":"Nano Today"},{"issue":"5","key":"2476_CR208","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1021\/acsnano.9b01383","volume":"13","author":"W Poon","year":"2019","unstructured":"Poon W, et al. Elimination pathways of nanoparticles. ACS Nano. 2019;13(5):5785\u201398.","journal-title":"ACS Nano"},{"key":"2476_CR209","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"YN Zhang","year":"2016","unstructured":"Zhang YN, et al. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332\u201348.","journal-title":"J Control Release"},{"issue":"19","key":"2476_CR210","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201900849","volume":"8","author":"C Fornaguera","year":"2019","unstructured":"Fornaguera C, et al. In vivo retargeting of Poly(beta aminoester) (OM-PBAE) nanoparticles is influenced by protein corona. Adv Healthc Mater. 2019;8(19):e1900849.","journal-title":"Adv Healthc Mater"},{"issue":"9","key":"2476_CR211","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2476_CR212","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tibtech.2016.07.006","volume":"35","author":"C von Roemeling","year":"2017","unstructured":"von Roemeling C, et al. Breaking down the barriers to precision cancer nanomedicine. Trends Biotechnol. 2017;35(2):159\u201371.","journal-title":"Trends Biotechnol"},{"issue":"3","key":"2476_CR213","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1021\/mp900093r","volume":"6","author":"R Juliano","year":"2009","unstructured":"Juliano R, et al. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm. 2009;6(3):686\u201395.","journal-title":"Mol Pharm"},{"issue":"1","key":"2476_CR214","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","volume":"181","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, et al. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181(1):151\u201367.","journal-title":"Cell"},{"issue":"3","key":"2476_CR215","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1124\/pr.111.005363","volume":"64","author":"JM Morachis","year":"2012","unstructured":"Morachis JM, Mahmoud EA, Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev. 2012;64(3):505\u201319.","journal-title":"Pharmacol Rev"},{"key":"2476_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114006","volume":"179","author":"N Krishnan","year":"2021","unstructured":"Krishnan N, Fang RH, Zhang L. Engineering of stimuli-responsive self-assembled biomimetic nanoparticles. Adv Drug Deliv Rev. 2021;179:114006.","journal-title":"Adv Drug Deliv Rev"},{"key":"2476_CR217","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","volume":"143","author":"ND Donahue","year":"2019","unstructured":"Donahue ND, Acar H, Wilhelm S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev. 2019;143:68\u201396.","journal-title":"Adv Drug Deliv Rev"},{"key":"2476_CR218","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"J Kim","year":"2021","unstructured":"Kim J, et al. Self-assembled mrna vaccines. Adv Drug Deliv Rev. 2021;170:83\u2013112.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"2476_CR219","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz I, et al. Highly efficient CD4\u2009+\u2009T cell targeting and genetic recombination using engineered CD4\u2009+\u2009cell-homing mRNA-LNPs. Mol Ther. 2021;29(11):3293\u2013304.","journal-title":"Mol Ther"},{"key":"2476_CR220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2023.04.043","volume":"166","author":"H Niu","year":"2023","unstructured":"Niu H, Zhao P, Sun W. Biomaterials for chimeric antigen receptor T cell engineering. Acta Biomater. 2023;166:1\u201313.","journal-title":"Acta Biomater"},{"issue":"12","key":"2476_CR221","doi-asserted-by":"publisher","first-page":"e1906128","DOI":"10.1002\/adma.201906128","volume":"32","author":"S Ramishetti","year":"2020","unstructured":"Ramishetti S, et al. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. Adv Mater. 2020;32(12):e1906128.","journal-title":"Adv Mater"},{"key":"2476_CR222","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2019.08.004","volume":"144","author":"S Patel","year":"2019","unstructured":"Patel S, et al. Brief update on endocytosis of nanomedicines. Adv Drug Deliv Rev. 2019;144:90\u2013111.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"2476_CR223","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","volume":"20","author":"S Liu","year":"2021","unstructured":"Liu S, et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat Mater. 2021;20(5):701\u201310.","journal-title":"Nat Mater"},{"issue":"1","key":"2476_CR224","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1021\/acsnano.8b05151","volume":"13","author":"M Wojnilowicz","year":"2019","unstructured":"Wojnilowicz M, et al. Super-resolution imaging of proton sponge-triggered rupture of endosomes and cytosolic release of small interfering RNA. ACS Nano. 2019;13(1):187\u2013202.","journal-title":"ACS Nano"},{"issue":"1","key":"2476_CR225","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/10717544.2020.1770371","volume":"27","author":"V Ayyadevara","year":"2020","unstructured":"Ayyadevara V, Roh KH. Calcium enhances polyplex-mediated transfection efficiency of plasmid DNA in Jurkat cells. Drug Deliv. 2020;27(1):805\u201315.","journal-title":"Drug Deliv"},{"issue":"27","key":"2476_CR226","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2301067120","volume":"120","author":"L Zheng","year":"2023","unstructured":"Zheng L, et al. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proc Natl Acad Sci U S A. 2023;120(27):e2301067120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2476_CR227","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt0202-143","volume":"20","author":"MV Maus","year":"2002","unstructured":"Maus MV, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial apcs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20(2):143\u20138.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2476_CR228","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/bit.27686","volume":"118","author":"E Harris","year":"2021","unstructured":"Harris E, et al. Nonviral gene delivery to T cells with lipofectamine LTX. Biotechnol Bioeng. 2021;118(4):1693\u2013706.","journal-title":"Biotechnol Bioeng"},{"key":"2476_CR229","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","volume":"332","author":"B Ghosh","year":"2021","unstructured":"Ghosh B, Biswas S. Polymeric micelles in cancer therapy: state of the Art. J Control Release. 2021;332:127\u201347.","journal-title":"J Control Release"},{"issue":"1","key":"2476_CR230","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","volume":"23","author":"M Metkar","year":"2024","unstructured":"Metkar M, Pepin CS, Moore MJ. Tailor made: the art of therapeutic mRNA design. Nat Rev Drug Discov. 2024;23(1):67\u201383.","journal-title":"Nat Rev Drug Discov"},{"key":"2476_CR231","doi-asserted-by":"crossref","unstructured":"Schmidt C, Schnierle BS. Self-Amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development. Pathogens. 2023;12(1):138.","DOI":"10.3390\/pathogens12010138"},{"key":"2476_CR232","doi-asserted-by":"crossref","unstructured":"Y\u0131ld\u0131z A, R\u0103ileanu C, Beissert T. Trans-Amplifying RNA: A journey from alphavirus research to future vaccines. Viruses. 2024;16(4):503.","DOI":"10.3390\/v16040503"},{"key":"2476_CR233","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","volume":"348","author":"X Liu","year":"2022","unstructured":"Liu X, et al. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84\u201394.","journal-title":"J Control Release"},{"issue":"5","key":"2476_CR234","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00018-015-2104-y","volume":"73","author":"B Pasquier","year":"2016","unstructured":"Pasquier B. Autophagy inhibitors. Cell Mol Life Sci. 2016;73(5):985\u20131001.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"2476_CR235","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1039\/C8BM01262H","volume":"7","author":"BR Olden","year":"2019","unstructured":"Olden BR, et al. Identifying key barriers in cationic polymer gene delivery to human T cells. Biomater Sci. 2019;7(3):789\u201397.","journal-title":"Biomater Sci"},{"issue":"1","key":"2476_CR236","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats. NPJ Vaccines. 2023;8(1):169.","journal-title":"NPJ Vaccines"},{"issue":"12","key":"2476_CR237","doi-asserted-by":"publisher","first-page":"e2006484","DOI":"10.1002\/smll.202006484","volume":"17","author":"F Oroojalian","year":"2021","unstructured":"Oroojalian F, et al. Immune cell Membrane-Coated biomimetic nanoparticles for targeted cancer therapy. Small. 2021;17(12):e2006484.","journal-title":"Small"},{"issue":"8","key":"2476_CR238","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/2159-8290.CD-17-1298","volume":"8","author":"S Sukumaran","year":"2018","unstructured":"Sukumaran S, et al. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov. 2018;8(8):972\u201387.","journal-title":"Cancer Discov"},{"issue":"9","key":"2476_CR239","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1021\/tx200051s","volume":"24","author":"M K\u00f6ncz\u00f6l","year":"2011","unstructured":"K\u00f6ncz\u00f6l M, et al. Cytotoxicity and genotoxicity of size-fractionated iron oxide (magnetite) in A549 human lung epithelial cells: role of ROS, JNK, and NF-\u03baB. Chem Res Toxicol. 2011;24(9):1460\u201375.","journal-title":"Chem Res Toxicol"},{"issue":"9","key":"2476_CR240","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1021\/tx800064j","volume":"21","author":"HL Karlsson","year":"2008","unstructured":"Karlsson HL, et al. Copper oxide nanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. Chem Res Toxicol. 2008;21(9):1726\u201332.","journal-title":"Chem Res Toxicol"},{"key":"2476_CR241","doi-asserted-by":"publisher","first-page":"121339","DOI":"10.1016\/j.biomaterials.2021.121339","volume":"281","author":"A Kheirolomoom","year":"2022","unstructured":"Kheirolomoom A, et al. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials. 2022;281:121339.","journal-title":"Biomaterials"},{"issue":"10","key":"2476_CR242","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee Y, et al. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med. 2023;55(10):2085\u201396.","journal-title":"Exp Mol Med"},{"key":"2476_CR243","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijbiomac.2020.11.205","volume":"168","author":"BS Unnikrishnan","year":"2021","unstructured":"Unnikrishnan BS, et al. Folic acid-appended galactoxyloglucan-capped iron oxide nanoparticles as a biocompatible nanotheranostic agent for tumor-targeted delivery of doxorubicin. Int J Biol Macromol. 2021;168:130\u201342.","journal-title":"Int J Biol Macromol"},{"key":"2476_CR244","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1163392","volume":"14","author":"S Wasti","year":"2023","unstructured":"Wasti S, et al. Ethical and legal challenges in nanomedical innovations: a scoping review. Front Genet. 2023;14:1163392.","journal-title":"Front Genet"},{"key":"2476_CR245","unstructured":"Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products. 2024; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-development-chimeric-antigen-receptor-car-t-cell-products"},{"key":"2476_CR246","unstructured":"Regenerative Medicine Advanced Therapy Designation. 2025; Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/regenerative-medicine-advanced-therapy-designation"},{"key":"2476_CR247","unstructured":"Breakthrough T. 2018; Available from: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/breakthrough-therapy"},{"key":"2476_CR248","unstructured":"Chemistry., Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). 2020; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug"},{"key":"2476_CR249","unstructured":"Launch of PRIME \u2013 Paving the way for promising medicines for patients. 2016; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/launch-prime-paving-way-promising-medicines-patients_en.pdf"},{"key":"2476_CR250","unstructured":"Conditional. marketing authorisation. 2016; Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/conditional-marketing-authorisation"},{"key":"2476_CR251","doi-asserted-by":"publisher","first-page":"114361","DOI":"10.1016\/j.ejpb.2024.114361","volume":"201","author":"SK S","year":"2024","unstructured":"S SK, et al. Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, japan, and India. Eur J Pharm Biopharm. 2024;201:114361.","journal-title":"Eur J Pharm Biopharm"},{"key":"2476_CR252","unstructured":"Strategy of. SAKIGAKE. 2014; Available from: https:\/\/www.mhlw.go.jp\/english\/policy\/health-medical\/pharmaceuticals\/dl\/140729-01-01.pdf"},{"issue":"3","key":"2476_CR253","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cpt.1383","volume":"106","author":"S Matsushita","year":"2019","unstructured":"Matsushita S, et al. A review of the regulatory framework for initiation and acceleration of patient access to innovative medical products in Japan. Clin Pharmacol Ther. 2019;106(3):508\u201311.","journal-title":"Clin Pharmacol Ther"},{"issue":"29","key":"2476_CR254","doi-asserted-by":"publisher","first-page":"e2502315","DOI":"10.1002\/smll.202502315","volume":"21","author":"N Desai","year":"2025","unstructured":"Desai N, et al. Nanoparticle therapeutics in clinical perspective: classification, marketed products, and regulatory landscape. Small. 2025;21(29):e2502315.","journal-title":"Small"},{"key":"2476_CR255","unstructured":"Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. 2014; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considering-whether-fda-regulated-product-involves-application-nanotechnology"},{"key":"2476_CR256","unstructured":"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. 2018; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and"},{"key":"2476_CR257","unstructured":"Drug, Products., Including Biological Products, that Contain Nanomaterials - Guidance for Industry. 2022; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-products-including-biological-products-contain-nanomaterials-guidance-industry"},{"issue":"30","key":"2476_CR258","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301956","volume":"12","author":"UM Musazzi","year":"2023","unstructured":"Musazzi UM, et al. Feeding next-generation nanomedicines to europe: regulatory and quality challenges. Adv Healthc Mater. 2023;12(30):e2301956.","journal-title":"Adv Healthc Mater"},{"key":"2476_CR259","unstructured":"Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product 2013; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator-liposomal-product-revision-2_en.pdf"},{"key":"2476_CR260","unstructured":"Reflection paper on surface coatings: general issues for consideration regarding parenteral administration of coated nanomedicine products 2013; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-surface-coatings-general-issues-consideration-regarding-parenteral-administration-coated-nanomedicine-products_en.pdf"},{"key":"2476_CR261","unstructured":"Joint MHLW. EMA reflection paper on the development of block copolymer micelle medicinal products 2013; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/joint-mhlwema-reflection-paper-development-block-copolymer-micelle-medicinal-products_en.pdf"},{"key":"2476_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105360","volume":"139","author":"EAJ Bleeker","year":"2023","unstructured":"Bleeker EAJ, et al. Towards harmonisation of testing of nanomaterials for EU regulatory requirements on chemical safety - a proposal for further actions. Regul Toxicol Pharmacol. 2023;139:105360.","journal-title":"Regul Toxicol Pharmacol"},{"key":"2476_CR263","unstructured":"Publication of Joint MHLW\/EMA reflection paper on the development of block copolymer micelle medicinal products 2014; Available from: https:\/\/www.pmda.go.jp\/files\/000272265.pdf"},{"key":"2476_CR264","unstructured":"Reflection paper on nucleic acids (siRNA)-loaded nanotechnology-based drug products 2016; Available from: https:\/\/www.pmda.go.jp\/files\/000272264.pdf"},{"issue":"17","key":"2476_CR265","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1039\/D0BM00558D","volume":"8","author":"R Foulkes","year":"2020","unstructured":"Foulkes R, et al. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8(17):4653\u201364.","journal-title":"Biomater Sci"},{"key":"2476_CR266","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105361","author":"KS Ku","year":"2024","unstructured":"Ku KS, et al. Current advancements in anti-cancer chimeric antigen receptor T cell immunotherapy and how nanotechnology May change the game. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25105361.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2476_CR267","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1021\/acsabm.4c01797","volume":"8","author":"T Kanp","year":"2025","unstructured":"Kanp T, et al. Exploring the potential of nanocarriers for cancer immunotherapy: insights into mechanism, nanocarriers, and regulatory perspectives. ACS Appl Bio Mater. 2025;8(1):108\u201338.","journal-title":"ACS Appl Bio Mater"},{"key":"2476_CR268","doi-asserted-by":"publisher","first-page":"809754","DOI":"10.3389\/fonc.2022.809754","volume":"12","author":"T Xin","year":"2022","unstructured":"Xin T, et al. -Vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front Oncol. 2022;12:809754.","journal-title":"Front Oncol"},{"key":"2476_CR269","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1125577","volume":"11","author":"W Oualikene-Gonin","year":"2023","unstructured":"Oualikene-Gonin W, et al. Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National agency for the safety of medicines and health products. Front Public Health. 2023;11:1125577.","journal-title":"Front Public Health"},{"key":"2476_CR270","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2023.01.005","volume":"89","author":"P Tan","year":"2023","unstructured":"Tan P, et al. Artificial intelligence aids in development of nanomedicines for cancer management. Semin Cancer Biol. 2023;89:61\u201375.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"2476_CR271","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/med4.62","volume":"2","author":"GM Raj","year":"2024","unstructured":"Raj GM, Dananjayan S, Gudivada KK. Applications of artificial intelligence and machine learning in clinical medicine: what lies ahead? Medicine Advances. 2024;2(2):202\u20134.","journal-title":"Medicine Advances"},{"issue":"2","key":"2476_CR272","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/med4.21","volume":"1","author":"H Ali","year":"2023","unstructured":"Ali H. Generative pre-trained transformer 4 in healthcare: challenges, opportunities, and recommendations. Medicine Advances. 2023;1(2):163\u20136.","journal-title":"Medicine Advances"},{"issue":"2","key":"2476_CR273","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.intonc.2025.03.006","volume":"1","author":"W Cai","year":"2025","unstructured":"Cai W. Deepseek AI: transforming medical AI with cost-efficiency, transparency, and privacy preservation. Intell Oncol. 2025;1(2):172\u20135.","journal-title":"Intell Oncol"},{"key":"2476_CR274","doi-asserted-by":"crossref","unstructured":"Chen Z, Saw PE. Integration in biomedical science 2024: emerging trends in the Post-Pandemic era. BIOI. 2024;5(1):1\u20132.","DOI":"10.15212\/bioi-2024-1001"},{"issue":"2","key":"2476_CR275","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10282","volume":"7","author":"VY Odeh-Couvertier","year":"2022","unstructured":"Odeh-Couvertier VY, et al. Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform. Bioeng Transl Med. 2022;7(2):e10282.","journal-title":"Bioeng Transl Med"},{"key":"2476_CR276","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.913287","volume":"9","author":"S Hort","year":"2022","unstructured":"Hort S, et al. Toward rapid, widely available autologous CAR-T cell therapy - Artificial intelligence and automation enabling the smart manufacturing hospital. Front Med Lausanne. 2022;9:913287.","journal-title":"Front Med Lausanne"},{"issue":"4","key":"2476_CR277","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41551-019-0351-1","volume":"3","author":"G Yamankurt","year":"2019","unstructured":"Yamankurt G, et al. Exploration of the nanomedicine-design space with high-throughput screening and machine learning. Nat Biomed Eng. 2019;3(4):318\u201327.","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"2476_CR278","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","volume":"41","author":"A Gottschlich","year":"2023","unstructured":"Gottschlich A, et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. 2023;41(11):1618\u201332.","journal-title":"Nat Biotechnol"},{"key":"2476_CR279","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137231","author":"N Martarelli","year":"2024","unstructured":"Martarelli N, et al. Artificial intelligence-powered molecular docking and steered molecular dynamics for accurate ScFv selection of anti-CD30 chimeric antigen receptors. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25137231.","journal-title":"Int J Mol Sci"},{"issue":"6625","key":"2476_CR280","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1126\/science.abq0225","volume":"378","author":"KG Daniels","year":"2022","unstructured":"Daniels KG, et al. Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science. 2022;378(6625):1194\u2013200.","journal-title":"Science"},{"issue":"13","key":"2476_CR281","doi-asserted-by":"publisher","first-page":"e1901989","DOI":"10.1002\/adma.201901989","volume":"32","author":"O Adir","year":"2020","unstructured":"Adir O, et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater. 2020;32(13):e1901989.","journal-title":"Adv Mater"},{"issue":"6","key":"2476_CR282","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41565-023-01323-4","volume":"18","author":"M Zhu","year":"2023","unstructured":"Zhu M, et al. Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures. Nat Nanotechnol. 2023;18(6):657\u201366.","journal-title":"Nat Nanotechnol"},{"issue":"8","key":"2476_CR283","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1073\/pnas.1620874114","volume":"114","author":"JE Dahlman","year":"2017","unstructured":"Dahlman JE, et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc Natl Acad Sci U S A. 2017;114(8):2060\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2476_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2023.103043","volume":"85","author":"S Hamilton","year":"2024","unstructured":"Hamilton S, Kingston BR. Applying artificial intelligence and computational modeling to nanomedicine. Curr Opin Biotechnol. 2024;85:103043.","journal-title":"Curr Opin Biotechnol"},{"issue":"6","key":"2476_CR285","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664\u201379.","journal-title":"Cancer Discov"},{"issue":"12","key":"2476_CR286","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","volume":"77","author":"DB Rubin","year":"2020","unstructured":"Rubin DB, et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 2020;77(12):1536\u201342.","journal-title":"JAMA Neurol"},{"issue":"9","key":"2476_CR287","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28(9):1848\u201359.","journal-title":"Nat Med"},{"issue":"3","key":"2476_CR288","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41551-022-00860-y","volume":"6","author":"M Kim","year":"2022","unstructured":"Kim M, et al. Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning. Nat Biomed Eng. 2022;6(3):267\u201375.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"2476_CR289","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.apt.2019.10.031","volume":"31","author":"K Tahara","year":"2020","unstructured":"Tahara K. Pharmaceutical formulation and manufacturing using particle\/powder technology for personalized medicines. Adv Powder Technol. 2020;31(1):387\u201392.","journal-title":"Adv Powder Technol"},{"issue":"1","key":"2476_CR290","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-024-02047-2","volume":"23","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, et al. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond. Mol Cancer. 2024;23(1):131.","journal-title":"Mol Cancer"},{"issue":"3","key":"2476_CR291","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.intonc.2025.06.005","volume":"1","author":"T Huo","year":"2025","unstructured":"Huo T, et al. Deep learning-based multimodal data fusion in bone tumor management: advances in clinical decision support. Intell Oncol. 2025;1(3):204\u201315.","journal-title":"Intell Oncol"},{"issue":"5","key":"2476_CR292","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.hlife.2024.05.002","volume":"3","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, et al. Cancer research revolutionized: unveiling the power of organoids and their therapeutic potential in oncology. hLife. 2025;3(5):216\u201336.","journal-title":"hLife"},{"issue":"3","key":"2476_CR293","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/med4.36","volume":"1","author":"D Yadav","year":"2023","unstructured":"Yadav D, Malviya R. Novel nanomaterials as photo-activated cancer diagnostics and therapy. Med Adv. 2023;1(3):190\u2013209.","journal-title":"Med Adv"},{"issue":"11","key":"2476_CR294","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13683","volume":"57","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity. Cell Prolif. 2024;57(11):e13683.","journal-title":"Cell Prolif"},{"issue":"12","key":"2476_CR295","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13727","volume":"57","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals. Cell Prolif. 2024;57(12):e13727.","journal-title":"Cell Prolif"},{"issue":"9","key":"2476_CR296","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124(9):5505\u2013616.","journal-title":"Chem Rev"},{"key":"2476_CR297","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","volume":"154\u2013155","author":"S Shah","year":"2020","unstructured":"Shah S, et al. Liposomes: advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154\u2013155:102\u201322.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2476_CR298","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, et al. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2\u201312.","journal-title":"Acc Chem Res"},{"issue":"17","key":"2476_CR299","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1021\/acs.accounts.1c00267","volume":"54","author":"N Song","year":"2021","unstructured":"Song N, et al. Ferritin: a multifunctional nanoplatform for biological detection, imaging diagnosis, and drug delivery. Acc Chem Res. 2021;54(17):3313\u201325.","journal-title":"Acc Chem Res"},{"issue":"1","key":"2476_CR300","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei S, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol. 2021;19(1):59.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2476_CR301","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01798-8","volume":"22","author":"P Kesharwani","year":"2023","unstructured":"Kesharwani P, et al. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol Cancer. 2023;22(1):98.","journal-title":"Mol Cancer"},{"key":"2476_CR302","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","volume":"138","author":"SM Dadfar","year":"2019","unstructured":"Dadfar SM, et al. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019;138:302\u201325.","journal-title":"Adv Drug Deliv Rev"},{"key":"2476_CR303","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119455","author":"SA Wickline","year":"2023","unstructured":"Wickline SA, Hou KK, Pan H. Peptide-based nanoparticles for systemic extrahepatic delivery of therapeutic nucleotides. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24119455.","journal-title":"Int J Mol Sci"},{"key":"2476_CR304","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jconrel.2022.11.009","volume":"352","author":"N Rajana","year":"2022","unstructured":"Rajana N, et al. Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer. J Control Release. 2022;352:1024\u201347.","journal-title":"J Control Release"},{"issue":"1","key":"2476_CR305","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","volume":"20","author":"RH Fang","year":"2023","unstructured":"Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20(1):33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2476_CR306","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12951-023-02064-1","volume":"21","author":"X Liu","year":"2023","unstructured":"Liu X, Xiao C, Xiao K. Engineered extracellular vesicles-like biomimetic nanoparticles as an emerging platform for targeted cancer therapy. J Nanobiotechnol. 2023;21(1):287.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2476_CR307","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, et al. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11(1):6080.","journal-title":"Nat Commun"},{"issue":"45","key":"2476_CR308","doi-asserted-by":"publisher","first-page":"20083","DOI":"10.1002\/anie.202008082","volume":"59","author":"X Zhao","year":"2020","unstructured":"Zhao X, et al. Imidazole-based synthetic lipidoids for in\u2005vivo mRNA delivery into primary T lymphocytes. Angew Chem Int Ed Engl. 2020;59(45):20083\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"21","key":"2476_CR309","first-page":"e2007421","volume":"33","author":"ARK Kumar","year":"2021","unstructured":"Kumar ARK, et al. Materials Improving Immune Cell Transfection Adv Mater. 2021;33(21):e2007421.","journal-title":"Materials Improving Immune Cell Transfection Adv Mater"},{"issue":"19\u201320","key":"2476_CR310","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1089\/hum.2021.173","volume":"32","author":"M Irving","year":"2021","unstructured":"Irving M, et al. Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen Receptor-T cells. Hum Gene Ther. 2021;32(19\u201320):1044\u201358.","journal-title":"Hum Gene Ther"},{"key":"2476_CR311","doi-asserted-by":"publisher","first-page":"p6644685","DOI":"10.1155\/2021\/6644685","volume":"2021","author":"V Lukjanov","year":"2021","unstructured":"Lukjanov V, Koutn\u00e1 I, \u0160imara P. CAR T-Cell production using nonviral approaches. J Immunol Res. 2021;2021:p6644685.","journal-title":"J Immunol Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02476-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02476-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02476-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:27:21Z","timestamp":1762295241000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02476-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":311,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02476-7","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}